IMV’s current clinical strategy focuses on combination immuno-oncology therapies incorporating our lead therapeutic candidate, DPX-Survivac, for advanced ovarian cancer and diffuse large B-cell lymphoma (DLBCL). Both of these tumor types are associated with poor outcomes and are thus high unmet medical needs.
We are currently engaged in multiple immunotherapy clinical trials leveraging DPX-Survivac and metronomic cyclophosphamide with Merck’s currently marketed anti-PD-1 drug, pembrolizumab, across multiple indications. In addition, we are also evaluating the potential of DPX-Survivac as a monotherapy for certain ovarian cancer patients.
Our goal with these programs is to confirm preliminary observations that DPX-Survivac may increase the vulnerability of these hard-to-treat tumors, while improving the utility of anti-cancer activity of these advanced agents.
Early clinical investigation of a second agent, DPX-E7, in human papillomavirus (HPV) cervical cancer is being pursued in an academic collaboration led by the Dana-Farber Cancer Institute.
Recurrent Ovarian Cancer
Study of DPX-Survivac Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer
Recurrent Survivin-Expressing DLBCL
Phase 2 Study of DPX-Survivac, Pembrolizumab and Cyclophosphamide in Patients With Recurrent Survivin-Expressing DLBCL
Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 2 Study of Pembrolizumab, DPX-Survivac and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer
Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer
Working at IMV brings you to the forefront of cutting-edge science and research for cancer and other serious diseases. We’ve worked hard to build a culture of innovation and collaboration.Learn more about life at IMV